Deep vein thrombosis landmark trials in treatment: Difference between revisions

	Deep Vein Thrombosis Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Causes
Differentiating Deep vein thrombosis from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Approach
Assessment of Clinical Probability and Risk Scores
Assessment of Probability of Subsequent VTE and Risk Scores
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Venography
CT
MRI
Other Imaging Findings
Treatment
Treatment Approach
Medical Therapy
IVC Filter
Invasive Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Special Scenario
Upper extremity DVT
Recurrence
Pregnancy
Trials
Landmark Trials
Case Studies
Case #1
Deep vein thrombosis landmark trials in treatment On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Deep vein thrombosis landmark trials in treatment
CDC on Deep vein thrombosis landmark trials in treatment
Deep vein thrombosis landmark trials in treatment in the news
Blogs on Deep vein thrombosis landmark trials in treatment
Directions to Hospitals Treating Deep vein thrombosis
Risk calculators and risk factors for Deep vein thrombosis landmark trials in treatment

Revision as of 17:04, 9 January 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [2]

@@ Line 1: / Line 1: @@
-{{Ventricular tachycardia}}
+{{Deep vein thrombosis}}
-{{CMG}}; '''Associate Editor-in Chief''': [[User:Avirupguha|Avirup Guha, M.B.B.S.]][mailto:avirup.guha@gmail.com]
+{{CMG}}; '''Associate Editor-In-Chief''': [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org]
 ==Landmark Clinical Trials==
-===Studies of secondary prevention of sudden cardiac death===
-. '''AVID (The Antiarrhythmics versus Implantable Defibrillators)'''
-* '''Strategy''': ICD vs medication either amiodarone or sotalol
-* '''Demographics''': Total: 1016 ICD: 507 Medications (predominantly amiodarone): 509 (80% with ischemic heart disease)
-* '''Mean EF''': 32 (inclusion<40)
-* '''Result''': Relative risk reduction: 1-year: 39% ; 2-year: 27% ; 3-year: 31% (p = 0.02)